Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1966 1
1995 1
1996 2
1997 1
2001 1
2009 1
2011 1
2012 2
2017 1
2021 2
2022 1
2024 0

Text availability

Article attribute

Article type

Publication date

Search Results

13 results

Results by year

Filters applied: . Clear all
Page 1
The antibacterial action of tetrachlorsalicylanilide.
Woodroffe RC, Wilkinson BE. Woodroffe RC, et al. Among authors: wilkinson be. J Gen Microbiol. 1966 Sep;44(3):343-52. doi: 10.1099/00221287-44-3-343. J Gen Microbiol. 1966. PMID: 5971384 No abstract available.
Estimated medical expenditure and risk of job loss among rheumatoid arthritis patients undergoing tofacitinib treatment: post hoc analyses of two randomized clinical trials.
Rendas-Baum R, Kosinski M, Singh A, Mebus CA, Wilkinson BE, Wallenstein GV. Rendas-Baum R, et al. Among authors: wilkinson be. Rheumatology (Oxford). 2017 Aug 1;56(8):1386-1394. doi: 10.1093/rheumatology/kex087. Rheumatology (Oxford). 2017. PMID: 28460083 Free PMC article. Clinical Trial.
Double-blind, placebo-controlled, dose-escalation study to evaluate the pharmacologic effect of CP-690,550 in patients with psoriasis.
Boy MG, Wang C, Wilkinson BE, Chow VF, Clucas AT, Krueger JG, Gaweco AS, Zwillich SH, Changelian PS, Chan G. Boy MG, et al. Among authors: wilkinson be. J Invest Dermatol. 2009 Sep;129(9):2299-302. doi: 10.1038/jid.2009.25. Epub 2009 Feb 19. J Invest Dermatol. 2009. PMID: 19225543 Free article. Clinical Trial. No abstract available.
A phase IIb dose-ranging study of the oral JAK inhibitor tofacitinib (CP-690,550) versus placebo in combination with background methotrexate in patients with active rheumatoid arthritis and an inadequate response to methotrexate alone.
Kremer JM, Cohen S, Wilkinson BE, Connell CA, French JL, Gomez-Reino J, Gruben D, Kanik KS, Krishnaswami S, Pascual-Ramos V, Wallenstein G, Zwillich SH. Kremer JM, et al. Among authors: wilkinson be. Arthritis Rheum. 2012 Apr;64(4):970-81. doi: 10.1002/art.33419. Epub 2011 Oct 17. Arthritis Rheum. 2012. PMID: 22006202 Free article. Clinical Trial.
13 results